The microbial flora of taxane therapy–associated nail disease in cancer patients - 28/02/18
Doi : 10.1016/j.jaad.2017.08.038
Cesar A. Virgen, MD, PhD a, Viswanath R. Belum, MD b, Mini Kamboj, MD c, Shari B. Goldfarb, MD d, Victoria S. Blinder, MD e, Ayca Gucalp, MD d, Mario E. Lacouture, MD b, ⁎ 
a Department of Dermatology, University of California Irvine, Irvine, California
b Dermatology Service, Memorial Sloan Kettering Cancer Center, New York, New York
c Infectious Diseases Service, Memorial Sloan Kettering Cancer Center, New York, New York
d Breast Medicine Service, Memorial Sloan Kettering Cancer Center, New York, New York
e Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York
∗Correspondence to: Mario E. Lacouture, MD, Dermatology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, 60th Street Outpatient Center, 16 East 60th St, Suite 407, Room 4312, New York, NY 10022.Dermatology Service, Department of MedicineMemorial Sloan Kettering Cancer Center60th Street Outpatient Center16 East 60th St, Suite 407, Room 4312New YorkNY10022
| Partially supported by the National Institutes of Health Cancer Center Support Grant P30-CA008748. Dr Virgen was supported by the American Academy of Dermatology Diversity Mentorship Program and the National Institutes of Health Training Grant T32-GM007198. Drs Belum and Lacouture are supported by the RJR Oncodermatology Fund at Memorial Sloan Kettering Cancer Center. |
|
| Disclosure: Dr Goldfarb receives research funding from Berg Health and HealthTell, and she is an advisory board member and consultant for Sermonix Pharmaceuticals. Dr Blinder is a consultant for Anthem Foundation, Pfizer, and the US Business Leadership Network. Dr Gucalp receives research funding from Innocrin Pharmaceuticals and Pfizer. Dr Lacouture reports that he is serving as a consultant to Quintiles, Boehringer Ingelheim, Genentech, Foamix, Infinity Pharmaceuticals, Janssen R&D, Novartis, and AstraZeneca. He has received research funding from Bristol-Myers Squibb and Berg. Drs Virgen, Belum, and Kamboj have no conflicts of interest to declare. |
|
| Reprints not available from the authors. |
© 2017
American Academy of Dermatology, Inc.. Publié par Elsevier Masson SAS. Tous droits réservés.
Vol 78 - N° 3
P. 607-609 - mars 2018 Retour au numéro
Article précédent
- Comparison of cyclic and continuous 308-nm excimer laser treatments for vitiligo: A randomized controlled noninferiority trial
- Jae Min Sung, Jung Min Bae, Hee Young Kang
- Satisfaction with care and likelihood to recommend ratings attributed to dermatology trainees
- Laura E. McDermott, Margaretta Midura, Vassiliki Papagermanos, Joslyn Kirby, Karolyn A. Wanat, Leah T. Belazarian, Cory Dunnick, Jessica S. Mounessa, Stephanie A. Savory, Nidhi Avashia-Khemka, Andrew Strunk, Amit Garg
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?